Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 382

1.

Nodal Failure After Chemoradiation and Magnetic Resonance Imaging Guided Adaptive BT in Cervical Cancer: A Subanalysis Within Embrace.

Nomden C, de Leeuw AA, Tanderup K, Lindegaard JC, Kirisits C, Haie-Meder C, Mahantshetty UM, Hoskin P, Segedin B, Potter R, Jürgenliemk-Schulz IM.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S12. doi: 10.1016/j.ijrobp.2016.06.044. No abstract available.

PMID:
27675572
2.

Importance of Technique, Dose Prescription, and Contouring in Cervix External Beam Radiation Therapy: Current and Future Practice in a Large Multicenter Study (EMBRACE).

Berger T, Assenholt M, Seppenwoolde Y, Mahantshetty UM, Jürgenliemk-Schulz IM, Hoskin P, Segedin B, Haie-Meder C, Georg D, Kirisits C, Pötter R, Lindegaard JC, Tanderup K.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E292. doi: 10.1016/j.ijrobp.2016.06.1359. No abstract available.

PMID:
27674292
3.

Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.

Irlam-Jones JJ, Eustace A, Denley H, Choudhury A, Harris AL, Hoskin PJ, West CM.

Br J Cancer. 2016 Aug 23;115(5):571-8. doi: 10.1038/bjc.2016.218. Epub 2016 Jul 21.

4.

Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.

Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Šegedin B, Mahantshetty U, Hoskin P, Jürgenliemk-Schulz I, Kirisits C, Lindegaard JC, Dörr W, Haie-Meder C, Tanderup K, Pötter R; EMBRACE collaborative group.

Radiother Oncol. 2016 Jul 7. pii: S0167-8140(16)31154-9. doi: 10.1016/j.radonc.2016.06.006. [Epub ahead of print]

PMID:
27396811
5.

Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.

Murray L, Mason J, Henry AM, Hoskin P, Siebert FA, Venselaar J, Bownes P; UroGEC/BRAPHYQS group of the GEC ESTRO.

Radiother Oncol. 2016 Aug;120(2):293-9. doi: 10.1016/j.radonc.2016.05.026. Epub 2016 Jun 29.

PMID:
27370205
6.

Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer.

Tanderup K, Fokdal LU, Sturdza A, Haie-Meder C, Mazeron R, van Limbergen E, Jürgenliemk-Schulz I, Petric P, Hoskin P, Dörr W, Bentzen SM, Kirisits C, Lindegaard JC, Pötter R.

Radiother Oncol. 2016 Jun 24. pii: S0167-8140(16)31117-3. doi: 10.1016/j.radonc.2016.05.014. [Epub ahead of print]

PMID:
27350396
7.

Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.

Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Šegedin B, Jurgenliemk-Schulz IM, Nomden C, Gillham C, McArdle O, Van Limbergen E, Janssen H, Hoskin P, Lowe G, Tharavichitkul E, Villafranca E, Mahantshetty U, Georg P, Kirchheiner K, Kirisits C, Tanderup K, Lindegaard JC.

Radiother Oncol. 2016 Apr 29. pii: S0167-8140(16)31018-0. doi: 10.1016/j.radonc.2016.03.011. [Epub ahead of print]

PMID:
27134181
8.

Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study.

Fokdal L, Sturdza A, Mazeron R, Haie-Meder C, Tan LT, Gillham C, Šegedin B, Jürgenliemk-Schultz I, Kirisits C, Hoskin P, Pötter R, Lindegaard JC, Tanderup K.

Radiother Oncol. 2016 Apr 21. pii: S0167-8140(16)31027-1. doi: 10.1016/j.radonc.2016.03.020. [Epub ahead of print]

PMID:
27113795
9.

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C.

Prostate. 2016 Jul;76(10):905-16. doi: 10.1002/pros.23180. Epub 2016 Mar 23.

PMID:
27004570
10.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

PMID:
26964030
11.

Hypofractionated radiotherapy for localized prostate cancer using three-dimensional conformal radiotherapy technique: 3 years toxicity analysis.

White R, Woolf D, Li S, Alonzi R, Osler P, Hoskin P, Hughes R.

Indian J Cancer. 2015 Oct-Dec;52(4):654-7. doi: 10.4103/0019-509X.178409.

12.

Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study.

Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, Mahantshetty U, Jürgenliemk-Schulz IM, Rai B, Cooper R, Dörr W, Nout RA; EMBRACE Collaborative Group.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1088-98. doi: 10.1016/j.ijrobp.2015.12.363. Epub 2015 Dec 29.

PMID:
26876955
13.

The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research.

Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27.

14.

Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Glynne-Jones R, Tan D, Hughes R, Hoskin P.

Nat Rev Clin Oncol. 2016 Jul;13(7):447-59. doi: 10.1038/nrclinonc.2015.218. Epub 2016 Jan 27. Review.

PMID:
26813935
15.

High dose rate brachytherapy for prostate cancer: Standard of care and future direction.

Thiruthaneeswaran N, Hoskin PJ.

Cancer Radiother. 2016 Feb;20(1):66-72. doi: 10.1016/j.canrad.2016.01.001. Epub 2016 Jan 22. Review.

PMID:
26811209
16.

Diagnosis and management of depression in children and young people: summary of updated NICE guidance.

Hopkins K, Crosland P, Elliott N, Bewley S; Clinical Guidelines Update Committee B.

Br J Sports Med. 2016 Feb;50(3):184-6. doi: 10.1136/bjsports-2015-h824rep.

PMID:
26782766
17.

Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.

Kirchheiner K, Nout RA, Lindegaard JC, Haie-Meder C, Mahantshetty U, Segedin B, Jürgenliemk-Schulz IM, Hoskin PJ, Rai B, Dörr W, Kirisits C, Bentzen SM, Pötter R, Tanderup K; EMBRACE Collaborative Group.

Radiother Oncol. 2016 Jan;118(1):160-6. doi: 10.1016/j.radonc.2015.12.025. Epub 2016 Jan 9.

PMID:
26780997
18.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.

Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.

19.

Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain.

Fallon M, Hoskin PJ, Colvin LA, Fleetwood-Walker SM, Adamson D, Byrne A, Murray GD, Laird BJ.

J Clin Oncol. 2016 Feb 20;34(6):550-6. doi: 10.1200/JCO.2015.63.8221. Epub 2015 Dec 7.

PMID:
26644535
20.

A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study.

Kaljouw E, Pieters BR, Kovács G, Hoskin PJ.

Radiother Oncol. 2016 Jan;118(1):122-30. doi: 10.1016/j.radonc.2015.10.021. Epub 2015 Nov 5.

PMID:
26549865
Items per page

Supplemental Content

Loading ...
Write to the Help Desk